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Gaps in current autism research: 




In advance of the 2019 INSAR Conference in Montreal, Quebec, Canada, I asked the 
members of the Autism Research Editorial Board and the Associate Editors to write 
short (approximately 300 word) mini-commentaries on what they considered to be the 
current gaps in research on autism spectrum disorder. The responses and styles were 
diverse and reflect research gaps ranging from basic biology to treatment trials to 
services for transition to adulthood. They reflect thoughts from countries around the 
world. While each of the contributions was done entirely independently, it is interesting 
how the theme of heterogeneity is found in many of them. There is also increasing 
concern over the lack of research on socioeconomic and cultural factors related to the 
diagnosis and treatment of autism spectrum disorder.  We hope that these comments 
will provide food for thought. 
 
I would like to thank the staff at Wiley, Ms. Christine (Chrissy) Murray and Victoria 
Scheibe for valuable help in producing this Commentary. 
 
 
David G. Amaral, Ph.D. 
The MIND Institute 
UC Davis 
 
Over the years I have become convinced that the genesis of autism spectrum disorder 
(ASD) occurs prenatally. There are many potential causes and both genetic and 
environmental factors appear to be at play. It is equally clear that the characteristics of 
ASD in a particular individual may change substantially throughout life. Autism severity 
may increase or decrease and co-morbid conditions such as gastrointestinal (GI) 
distress or epilepsy may decrease or appear without warning. While there are a number 
of large-scale genetic studies under way, these rarely take environmental factors into 
consideration. Environmental studies are increasingly collecting data from families early 
during, or even before pregnancy, but generally are unable to comprehensively evaluate 
brain and behavioral development of the offspring. Thus, one major gap that I believe 
still exists is a large-scale, longitudinal survey of families that begins prior to pregnancy 
and then follows children into at least adolescence. The study that I have in mind would 
collect detailed environmental data, would carry out sophisticated genetic analysis of 
the family and then equally comprehensively document brain development using 
magnetic resonance imaging and behavioral development using sophisticated 
behavioral probes. Of course to provide the most comprehensive picture of ASD, 
participants with all levels of severity would be included and the cohort would be sex 
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balanced. The hope would be that this would go some way towards defining predictors 
of improvement as well as emerging medical problems such as epilepsy. Expensive? 
Yes, but if we finally started to have some definitive answers about the trajectories of 
ASD, it might save money in the long run. Beyond this, I believe that there is a gap in 
trying to determine how the core and comorbid features of ASD are linked. For example, 
the amygdala is clearly involved in the neural alterations associated with ASD. And, the 
amygdala can also influence gastric secretion and gastrointestinal problems. What is 
not known is whether there is a link between alterations in the amygdala and GI 
problems in ASD. Does one cause the other? Is the presence of abnormal amygdala 
structure or function a predictor of GI problems? Finally, there is an enormous gap in 
understanding the neural alterations in the autistic brain at the cellular and circuit levels. 
It is the hope of those involved in Autism BrainNet (autismbrainnet.org) that an increase 
in the availability of postmortem brain specimens will encourage researchers to begin to 
fill this gap. 
 
 
George M. Anderson, PhD 
Child Study Center and Dept. of Lab. Medicine 
Yale University School of Medicine 
 
Mind the Gap, Mind the Heterogeneity 
A major shortcoming of most research in the autism realm has been the failure to take 
into account the heterogeneity of the Autism Spectrum Disorder (ASD) category when 
designing studies. Most studies -- be they genetic, neurobiological, or behavioral— have 
compared an ASD group to a typically developing group. Findings are rarely replicated 
and any group mean differences observed are then attributed to all members of the 
group despite the invariable large overlap in individual data points across groups. 
Though many have recommended a more dimensional, fractionable, Research Domain 
Criteria approach, this strategy has not been widely adopted. Instead, genetic studies 
continue to search for risk variants of small effect in complex groups, biological research 
proceeds in its attempt to find unitary underlying commonalities in members of the ASD 
category, and early detection research continues to search in vain for markers with 
clinically useful specificities and sensitivities. On the one hand, this state of affairs can 
be attributed to an understandable attachment to diagnostic and categorical labels. On 
the other, the paucity of validated dimensional instruments for the multiple relevant 
dimensions presents a practical obstacle. Also, the power of the language of “disorder” 
and “symptoms”, and the influence of the implicit medical model, should not be 
underestimated. 
 
While no one expects the journal Autism Research to be renamed Social Atypicality 
Research, autism research might benefit from a thorough and continuing consideration 
of how the term “autism” is used, applied and defined, and how it can mislead. Only 
when the behavioral dimensions relevant to the social atypicality realm are fully 
characterized, and we have some idea how they interact within a particular individual, 
will we be able to discern genetic and biological underpinnings, and predict and possibly 
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alter development. In short, in social atypicality research we need to be focused on 
characterization rather than categorization. 
 
 
Anthony Bailey, M.D. 
University of British Columbia 
 
Despite a welcome recent shift, a very small proportion of ASD research focuses on the 
needs of affected adults, despite these individuals constituting the bulk of the ASD 
population and incurring over 90% of ASD related costs. The significance of this 
research gap is amplified by the relative lack of services for adults with ASD, which is 
particularly marked for those with intellectual abilities within the typical range. 
 
Three broad research areas stand out. First, the strong associations between ASD and 
diverse comorbid mental health conditions is now well documented and the reasons for 
these associations represent a research field in their own right. Arguably it is the 
association with anxiety disorders that causes the greatest overall impairment, and 
although many individuals with comorbid anxiety will show a positive response to 
psychotherapy and/or pharmacology, residual levels of anxiety can remain troublingly 
high. Consequently, there is a pressing need to understand the neurobiological basis of 
anxiety in this population in order to facilitate discovery of new antianxiety drugs or drug 
repurposing. Additionally there appear to be systemic barriers to adults with ASD 
obtaining equitable access to adult mental health services across many different 
countries. The overall problem is widely recognized, but there has been almost no 
attempt to identify the underlying obstacles to service access; is the main issue limited 
knowledge amongst mental health professionals about ASD in adulthood, or a belief 
that a super specialized skill set is required to manage these individuals, and to what 
extent are the barriers facing adults with ASD the same as or different from those facing 
adults with intellectual disability? 
 
Secondly, success in higher education or the workplace still eludes many adults with 
ASD. Both entry into higher education and graduation rates are relatively low compared 
to the general population and the issue is becoming more pressing as a greater 
proportion of adolescents with ASD can now benefit from higher education and recent 
changes in the nature of work require an increasingly well-trained workforce. There has 
been a welcome increase in higher education related research in the last three years, 
much of it documenting the utility of focused support and peer mentoring schemes. 
Nevertheless, approaches still vary widely between institutions and are not always 
based on empirical evidence. What are the best ways to support adult learners with 
ASD and to help them achieve optimal outcomes? And how can we answer these 
questions unless we develop standardized assessment tools to identify individual 
strengths, weaknesses and needs at entry into higher education. Even on graduating 
from higher education, employment levels of adults with ASD still do not attain those of 
the general population and overall employment rates for affected adults remain 
abysmal. Focused government initiatives have had modest impact on employment rates 
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or the dual scourges of underemployment or a job rather than a career. There appear to 
be multiple barriers to employment, but little guidance from the current research 
literature as to which of these deserve most attention. Does the way forward lie in giving 
individuals with ASD enhanced training on pre-employment skills, or in offering 
incentives to employers? And, when individuals are employed, should maximizing their 
skills be left to employers alone or is outside ASD expertise or advocacy also required? 
 
Finally, adult relationships are protective for both psychological and physical health, but 
in the context of ASD, we simply do not know the number and quality of extra-familial 
relationships that are sufficient for good health and high quality of life. Concern about 
social isolation is a common worry of parents of individuals with ASD and there is a gap 
in our understanding about how best to help individuals develop relationships that are 
both enjoyable and sustainable. 
 
 
Raphe Bernier, Ph.D. 
University of Washington 
 
There are a number of gaps in autism research that are sprinkled throughout several 
different domains, from genetics, to neuroscience, to intervention. Even in areas that 
have been well studied, gaps remain. These pockets of gaps are reflective of the gaps 
in adaptive skills observed in many children with autism, in which some skills are intact, 
but others (even more foundational adaptive skills) are not developed. 
 
One primary gap concerns intervention. In order to hasten the pace of intervention 
research we need objective markers to monitor treatment outcome. A major obstacle 
concerns our limited ability to monitor treatment progress in an objective, quantitative, 
and efficient manner. Relatedly, we also need to establish more specific, reliable 
predictors for who will positively respond to different types of intervention. We need to 
know who will respond to which type of empirically supported treatment approach. And, 
clearly we need to identify new treatments for those individuals who are not responding 
to existing interventions. 
 
A second major gap concerns the etiology of autism. While significant gains have been 
made in autism genetics through collaborative efforts, the assembly of large cohorts, 
and new sequencing advances, there still exist major gaps. These gaps are in the 
identification of which genes and genetic events are contributing to autism risk, how 
structural variation and common variation intersect, and how genetic risk interacts with 
environmental or other background risk. This foundational gap in understanding etiology 
impedes progress in understanding the pathophysiology and mechanism. 
 
A third major gap concerns the identification of novel, efficient diagnostic processes. 
Given that an autism diagnosis currently serves as a gateway to services for many, 
immediate access to diagnostic evaluation is critical. We need to identify, novel, valid 





Somer Bishop, Ph.D. 
University of California, San Francisco 
 
Despite many years of calls for more longitudinal research, this critical gap remains. 
Much has been learned from existing longitudinal cohorts, but there is now a pressing 
need to recruit contemporary cohorts of children diagnosed with ASD and follow them 
into adulthood. It is clear that attempts to subtype within ASD are not likely to be 
successful unless we can subtype by trajectories. Our ability to offer information to 
parents and policy makers about what children diagnosed today need now, and what 
they will need in 10 or 20 or 30 years, is dependent on recruitment of new longitudinal 
cohorts. These efforts would also be enhanced by increased collaboration between 
experts in assessment and treatment, as well as in-the-moment coordination between 
clinical researchers and those interested in neurobiology and genetics (e.g., genetic 
testing for children with ASD enrolled in longitudinal studies). 
 
 
Gene Blatt, Ph.D. 
Hussman Institute for Autism 
 
Autism research is thriving with many informative and well-constructed studies in a 
variety of fields, including early detection and intervention, imaging and genetic studies. 
Numerous mouse models (studying developmental processes, behavior, physiology, 
etc. are attempting to demonstrate that single gene mutations can cause autism-related 
functions and then “rescue” those deficits with compounds that target receptors in 
particular pathways.  The problem is providing convincing evidence that findings are 
truly translational in nature.  Do genes act differently in humans versus mice? What 
about gene variants in humans causing up- or down-regulated gene expression and/or 
epigenetic effects? The challenge to neuroscientists is to build viable well thought out 
models with translational value.  For human studies, increasing iPSC studies can 
examine development of human autism cell types in an attempt to identify from very 
early on whether neurite outgrowth, synapse formation and ultimately circuitry develops 
normally in autism lines versus controls.  Now that Autism BrainNet is operative, more 
researchers should compose viable experiments and aims in postmortem ASD cases 
versus controls in specific brain areas where studies have identified structural/functional 
changes.  Now that more ASD cases are available to researchers, studies can 
potentially include males versus females and/or in children versus adults For the first 
time, the “n” for postmortem cases has doubled, making  postmortem studies 
informative and possibly providing better evidence despite the high variability in any 
ASD study. As imaging techniques improve in resolution for both white matter tracts and 
gray matter changes and/or functional differences, more studies in idiopathic autism 
cases are needed as most imaging studies have been carried out in high functioning 
subjects. In summary, many strides have been made in recent years toward better 
understanding of  the underlying mechanisms and toward identifying changes in area 
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activation and behavior.  What is lacking is better animal models with translational value 
and more human-based studies that cover a range of individuals on the spectrum, in an 
attempt to obtain a wider understanding of structural/functional changes and how to 
best approach improving the lives of people with ASD and their families. 
 
 
Ricardo Canal-Bedia, Ph.D. 
Instituto Universitario de Integración en la Comunidad (INICO) 
Universidad de Salamanca, Spain 
 
In the last 20 years, there has been notable progress towards identifying early signs and 
studying their predictive value. Currently, it is possible to identify some children at risk of 
ASD before 24 months in low-risk populations and 12 months (or sometimes earlier) in 
high-risk groups (siblings of children with ASD). However, the greatest gaps for people 
who later will develop ASD are found in the first year of life. The age of 12 months 
seems to be a difficult frontier to overcome, especially for population screening, as 
behavioral indicators alone are not enough. Only some early biomarkers are currently 
being studied (mainly in samples at genetic risk), which could potentially be useful in an 
early identification protocol (Emerson et al., 2017; Hazlett et al., 2017; Samango-
Sprouse et al., 2015). For that reason, a priority will be to move towards the 
identification of neuropathological processes in early brain development, including the 
prenatal phase (Muhle, Reed, Stratigos, & Veenstra-VanderWeele, 2018). There are 
several studies on early biomarkers but only a fewer have proven some predictive value 
to improve early detection and diagnosis. In addition, it has been suggested that 
biomarkers are needed to stratifying different subgroups of subjects within the spectrum 
(Pelphrey, 2017) and studies are needed to combine these biomarkers with early 
behavioral indicators. Further research in this area is also essential in order to develop 
accurate measures that help to assess progress on early interventions (behavioral or 
pharmacological). Finally, another important aspect to highlight is how to transfer the 
knowledge about risk factors, biomarkers and behavioral signs into practical application 
for the professionals working with people with ASD. 
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Tony Charman, Ph.D., C Clin Psychol 
Institute of Psychiatry, Psychology & Neuroscience 




Whilst recognition of the variability and heterogeneity of autism, from its aetiological 
causes to its varied presentation between individuals and within an individual across the 
developmental time course, is to be welcomed it continues to present pervasive 
challenges to autism science and clinical progress. So many of the scientific paradigms 
that we use in fields as diverse as genetics to neuroimaging to intervention trials 
traditionally ‘work better’ if one is studying a more homogeneous group of individuals. 
To some degree the heterogeneity issue places limits on critical aspects of a mature 
clinical science, including replication and generalisation of findings, that lessen the 
impact of the work that we do to improve the lives of individuals with autism. Whilst 
autism is not alone in medical conditions in facing such challenges, we need to embrace 
heterogeneity by adopting new and paradigm-shifting approaches that are barely 
emerging. This places an onus on all stakeholders in the autism research field – from 
research funders to research participants and, of course, including research scientists – 
to develop these new paradigms to accelerate the pace of much-needed change. I’m 
not sure what the answers will be but the challenge will not recede without creativity, 
application and a little good fortune. 
 
 
Geraldine Dawson, Ph.D. 
Duke Center for Autism and Brain Development 
Duke University 
 
As new potential treatments for improving outcomes and quality of life for individuals 
with autism are developed, robust methods for evaluating their efficacy are critical for 
moving the field forward. While the need for more effective treatment is urgent, we 
struggle with the ability to design and carry out well-designed clinical trials.  Part of that 
difficulty arises from the fact that autism spectrum disorder (ASD) is inherently 
phenotypically and biologically complex, and both behavior and biology change across 
development.  Adding to phenotypic and biological complexity is the variability in 




To improve our ability to evaluate new autism treatments, research is needed to 
address a wide range of issues that affect how ASD clinical trials should be designed to 
optimally determine efficacy.  These include: the need for natural history studies that 
incorporate clinical trial outcome measures so that studies can be adequately powered 
to separate changes reflecting treatment response from developmental changes; 
standardized approaches for assessing and accounting for a wide range of confounding 
factors, such as use of other interventions during the clinical trial, and the presence of 
co-morbidities, genetic and other biological features that might be related to treatment 
response; methods for addressing the large placebo effect inherent in most ASD clinical 
trials; commonly agreed upon standards for outcome measures and rater training; and 
the development and validation of more sensitive, objective, and reliable biomarkers 
and outcome measures. With respect to outcome measures, research on the use of 
digital behavioral measures have the potential to offer more precise, objective, scalable 
quantification of behavioral outcomes.  In summary, given the pressing need for more 
effective treatments across the lifespan, research leading to improved methodology for 
autism clinical trials should be a high priority. 
 
 
Petrus J de Vries, M.B.,Ch.B, FRCPsych, Ph.D 
Centre for Autism Research in Africa, Division of Child & Adolescent Psychiatry 
University of Cape Town, Cape Town, South Africa 
 
The ASD Research GAP in low- and middle-income countries 
 
A recent study of the global burden of developmental disabilities in under 5-year olds 
(GRDDC, Lancet Global Health) identified that 95% of all under 5-year olds with 
developmental disabilities (including ASD), live in low- and middle-income countries 
(LMIC). Strikingly, sub-Saharan Africa (SSA) and South-East Asia showed the greatest 
rise in developmental disabilities over the last 30 years of all global regions. In stark 
contrast to this growing recognition and rapidly growing need, very little ASD research is 
conducted in LMIC. A scoping review of ASD research in SSA showed, for instance, 
that less that 1% of the world’s ASD research originated from SSA (Franz et al., Autism 
Research, 2017). 
 
LMIC represent not only low socio-economic status, but are also characterized by highly 
diverse, multilingual and multicultural communities. South Africa is an interesting case 
example: the country has a population of 55 million people who speak 11 official 
languages, is categorized by the World Bank as an ‘upper-middle’ income country, but 
is also the nation with the highest Gini coefficient, suggesting the greatest socio-
economic disparities. Associated with this comes some of the greatest health disparities 
in the world (Franz et al., 2018). ASD services in the country are highly limited, exist 
almost exclusively in urban communities, and provide little more than diagnostic 
services to the majority of the population, who cannot afford to pay for (mostly non-




In the scoping review on ASD in SSA, Franz and colleagues (2017) identified major 
gaps in almost all areas of research. Notable gaps included the absence of any 
epidemiological studies of ASD, no early intervention studies, no research on adults 
with ASD, and virtually no knowledge of health and education systems, use of 
technology, or perspectives of stakeholders. Research, on the whole, was of relatively 
poor quality (Franz et al., 2017). 
 
It seems clear that ASD and related developmental disabilities represent one of the 
major challenges of the 21st century. Much is required to understand the ASD research 
gaps in parts of the world where most people with ASD live. A global, collaborative 
research effort will be required to understand the needs of these culturally, linguistically 
and socio-economically diverse communities, systems and stakeholders, and specific 
efforts should be made by the global ASD research community to support advocacy for 
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Emanuel Dicicco-Bloom, M.D. 
Department of Neuroscience and Cell Biology/Pediatrics 
Rutgers Robert Wood Johnson Medical School 
 
It’s time for autism neural stem cell research 
 
Since autism is a uniquely human disorder, understanding its pathogenesis will require 
investigation of etiological factors, like genes and environment, in the human brain. A 
major challenge, and significant gap, is that many contributory factors act during early 
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brain development, a prenatal period that is difficult to access and study. Evidence of 
early fetal developmental dysregulation comes from studies of postmortem tissue and 
MRI imaging. Moreover, newer genetic studies suggest autism risk genes largely 
converge on the developing cerebral cortex between gestational weeks 8 and 24, when 
neural precursor cells (NPCs) are undergoing proliferation, migration, and initial 
differentiation. No doubt, tremendous progress in understanding the roles of genetic 
factors has derived from mouse models where expression of specific risk genes is 
manipulated eg. the monogenic syndromes that exhibit autism symptoms, such as Rett, 
Fragile X, Tuberous Sclerosis, and high penetrance copy number variants, like 16p11.2. 
However, the majority (80%) of autism is genetically undefined (idiopathic) and 
monogenic risk genes contribute little, so genetic models cannot be generated. Further, 
even when mouse models have been analyzed for behavior, structure, neural circuits, 
and synaptic functions, the earliest periods of cortical neurogenesis have been 
neglected, missing the time and place where convergent genetic analyses point. It is 
also obvious that animal models can only take us so far: Neurons in the mouse cerebral 
cortex are generated in only 6 days, whereas the same process takes 6 months (1st & 
2nd trimesters) in humans. Thus, to overcome these developmental, genetic, and 
functional differences between animals and humans, we should now focus our attention 
on human NPCs generated from individuals with autism, both idiopathic and genetically-
defined, in which the person-specific genetic signature and family background are 
maintained. The advent of human induced pluripotent stem cell (iPSC) technology now 
allows us to create the diverse stages of developing NPCs and more mature neurons. 
This revolution is now well underway in academia and industry with the expectation that 
we will identify neurobiological pathways and mechanisms underlying genetic and 
environmental contributions to human disease. In turn, we hope to identify autism 
subgroups based on etiological pathways at cellular and circuit levels that can be 
targets for therapeutic interventions. This approach, already beneficial in cancer, 
warrants further development and support as we struggle with the incredible 
heterogeneity of autism spectrum disorders. 
 
 
Cheryl Dissanayake, Ph.D. 
Autism Research Centre, La Trobe University 
 
Despite calls for more research on adolescents and adults, and a new journal dedicated 
to adults, there remains limited empirical research on the presentation of autism in 
adults and how its’ features impact their lives. Without this knowledge, we can do little to 
progress and provide evidence-based supports to improve the quality of lives of those 
living with autism.  
 
Of particular need is research that is co-produced with autistic researchers, and we 
need to focus on not just research on adulthood but training autistic scholars to 
contribute to these research efforts. Listed below are topics begging empirical 




Aging and autism (with particular attention to vulnerability to medical disease; and 
service provision) 
 
Parenting with autism 
 
Drug and alcohol use in autism 
 
Self-injury and autism (see work by Chris Oliver) 
 
Autism and the criminal justice system 
 
RRBs in adulthood (with attention on the presentation of circumscribed interests in 
adults) 
 
Good empirical research on employment to enhance understanding of enables and 
barriers to employment and good alternatives for recruitment and employee retention  
 
Inter-relationships of comorbid conditions and their relationship to core autism 
symptomatology and outcomes across the lifespan (as well as intervention for co-
morbid conditions) 
 
Minimally verbal autistic people and those with severe autism overlooked across all 
stages of development and inquiry 
 
One of the overarching gaps is advancement of theory in autism research - whereby 
having criticized much of what was available which was found to be of little 




Yoko Kamio, M.D., Ph.D. 
Institute for Education and Human Development 
Ochanomizu University 
 
Changing definition of ASD and dimensional approach 
 
There is a long history of delineating the border that separates affected individuals from 
unaffected ones. In a sense, such effort to define the pathological conditions strictly has 
contributed to an advance in autism research. On the other hand, evidence indicates 
that the autistic condition lies on the spectrum from the extreme end to the milder end 
without a discrete cutoff at both behavioral and biological levels. The subthreshold 
condition that does not meet such a strictly defined diagnostic criteria has not long been 
paid attention to from clinicians and autism researchers when autism is considered as 
an entity. For example, there has been little focus on the possible early intervention for 
subthreshold children. Most early intervention studies chose children with ASD defined 
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strictly as research subjects. However, recent research suggests that subthreshold 
autistic traits persist throughout the life, and many maladapted adults who were 
subthreshold can be diagnosed as ASD using loosened DSM-5 criteria. 
 
Similarly as in ASD comorbidity with multiple neuropsychiatric conditions occurs so 
frequently, subthreshold autistic symptoms are also often observed in other 
neuropsychiatric conditions such as ADHD, depression, bipolar disorder, and 
schizophrenia. Such behavioral overlap seems consistent with similarity at the level of 
brain structure, neural network, cognitive features, suggesting that autistic symptoms 
are not ASD-specific but also a cross-diagnostic element. Thus, future autism research 
should extend its scope using dimensional approach cross diagnostically beyond ASD 
vs. TD, which will not overlook a sub-group consisting of the heterogenous ASD and will 
contribute to both neuroscience and general clinical practice (not necessarily highly 
specialized clinical practice). To do so, dimensional approach should be validated cross 
diagnostically, like the RDoC approach proposed by NIMH tries to do. 
 
Parenting a child with ASD revisited 
 
This theme has been and still is likely to evoke unpredictable emotional reaction (and 
also irrational thought) in not only parents but also health professionals. The idea that 
wrong parenting causes autism has no scientific evidence, and no one would disagree 
with it. However, it is true that parent-child interactions are influenced by the presence 
of ASD in the child. As a result of it, there is a high risk for maltreatment towards a child 
with ASD or developing depression among mothers. Especially how the mother’s role is 
recognized and valued in the society and what mothers themselves desire for their child 
regarding early development differs by cultural norm and stigma. For example, it is 
reported that Japanese mothers may emphasize emotional bonding and maturity 
whereas American mothers focus on verbal expressiveness and social skills. In 
addition, since autistic symptoms and mental health problems tend to aggregate within 
a family, there is a sub-group of vulnerable mothers. Future clinical or public health 
research related to autism should focus on vulnerable families based on evidence 
derived from community-based longitudinal studies for children with ASD and families, 
although most clinical studies examine short-term effectiveness for children who were 
chosen from the families participating in research. 
 
Finally, I hope that in the future multi-cultural, multi-dimensional studies of ASD would 
reveal the mystery of the diversity related to the ASD syndrome and its development. 
 
 
Rajesh Kana, Ph.D. 
Dept. of Psychology 
University of Alabama at Birmingham 
 
One of the prominent hypotheses pertaining to the neurobiological origins of autism 
spectrum disorder (ASD) is the disrupted brain connectivity hypothesis (Just et al., 
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2004; Kana, Libero, Moore, 2011). Despite the relative consistency of connectivity-
related neuroimaging findings in ASD, one of the main issues hampering its reliability is 
its relatively poor specificity. For example, similar to ASD, disrupted connectivity has 
been found repeatedly in disorders like schizophrenia and attention deficit hyperactivity 
disorder (ADHD). An important avenue for future research in ASD is to generate 
studies, especially neuroimaging studies, along the lines of the NIH Research Domain 
Criteria (RDoC) initiative. Comparison of disorders like ASD, ADHD, and schizophrenia 
may provide more insight into the nature and extent of the disrupted connectivity 
hypothesis. A second potential gap involves investigating, estimating, and separating 
the effect of comorbid conditions with ASD and its impact on research findings. 
Comorbid conditions like ADHD with ASD has been a difficult problem for researchers. 
While researchers understand the significance of this problem at a conceptual level, 
practically they face an uphill task to identify cleaner/homogeneous sample. Studying 
the effect of comorbid conditions would be an important direction for future studies in 
ASD. Finally, intervention-related neuroimaging studies are badly needed in autism. The 
need for evidence-based intervention practices cannot be overemphasized. 
Neuroimaging studies that specifically target the effectiveness of existing cognitive and 
behavioral interventions in ASD and also testing the impact of novel interventions on the 
neurobiology of autism as well are needed. 
 
 
Naila. Z. Khan, MBBS, FCPS, PhD 
Clinical Neurosciences Center 
Bangladesh Protibondhi Foundation 
 
A government epidemiological survey of Neurodevelopmental Disorders (NDDs) 
including Autism in children aged 0-9 years in 2013 (total number of children=7280) in 
Bangladesh1 ascertained that the prevalence of all types of neurodevelopmental 
impairments (NDIs) was 185/1000, with the highest numbers of children with cognitive 
impairments (158/1000). Prevalence of NDDs was 70/1000. Within this category the 
prevalence of Autism Spectrum Disorder (ASD) was 1.55/1000; with significant disparity 
in the prevalence of ASD in rural (0.68/1000) versus urban middle and high income 
(30/1000) populations. A recent survey of ASDs showed similar trend, i.e., prevalence 
of ASD was 14/10,000 in rural populations versus 25/10,000 in urban populations2. This 
survey did not disaggregate relevance by family income.  Case load of ASDs in clinical 
settings also show a similar disparity by family socioeconomic status.  In the 15 Child 
Development Centers established within government tertiary hospitals serving the 
lowest income populations across the country3, there was a rising case load of ASDs in 
their General Developmental Assessment Clinic by family income, ie, within low (6%), 
low middle (15%), middle (34%) and high income (44%) families3, page 24. These 
disparities in prevalence in epidemiological surveys and incidence in clinical settings by 
urban/rural residence and by wealth quintile pose questions regarding the antecedents 
or risk factors leading to ASDs in different populations within the same country, even 
with sociopolitical, geographical and cultural similarities, and where the professional 
skills, scales, tools, and procedures applied for the assessment and diagnosis of ASD 
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were the same. Epigenetic studies are needed to explore the underlying reasons for 
such differences, so that the country’s scarce resources can be allocated for the best 
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Frank Kooy, Ph.D. 
Department of Medical Genetics 
University of Antwerp 
 
Over the last years, we have seen an impressive increase in the number of genetic 
diagnoses in autism. The introduction and maturation of next-generation sequencing 
technologies brought large-scale sequencing projects to the forefront of autism 
research. The progress is impressive both in the number of diagnoses made and in the 
number of novel genes discovered (Deciphering Developmental Disorders Study, 2017; 
Iossifov et al., 2014; De Rubeis et al., 2014; Stessman et al., 2017). The latest meta-
analyses suggest that over a hundred genes have now been identified that, when 
disrupted, cause in autism (Coe et al., 2019; Satterstrom et al., 2018). While the 
increase in genetic knowledge is by all measures spectacular, several challenges lie 
ahead of us. First of all, the individual genetic causes, even the most frequently mutated 
genes including ADNP, CHD8 and SCN2A, none counts for more than a percentage of 
the total number of cases (Bernier et al., 2014; Helsmoortel et al., 2014; Weiss et al., 
2003). The unprecedented genetic heterogeneity hampers the collection of larger 
cohorts of patients with the same underlying genetic ethiology, necessary for fine-tuning 
the full spectrum of clinical symptoms (Arnett et al., 2018; Van Dijck et al., 2019) and 
discourages initiatives for therapy because of the small patient population for any given 
disorder.   A second challenge is the interpretation of the missense variants identified in 
the patients in the gene-identification studies (Coe et al., 2019; Deciphering 
Developmental Disorders Study, 2017; Satterstrom et al., 2018). Essentially all 
established diagnoses to date have either a gene inactivating variant or a missense 
variant belonging to the 0.1% most pathogenic sequence alterations, as judged by 
having a CADD  score of >  30 (Kircher et al., 2014), while we are uncertain of the 
relevance of the great majority of the missense variants. Furthermore, it can be noted 
that the diagnoses are almost exclusively made in autistic patients on the severe end of 
the clinical spectrum, many of those co-morbid with ID. A huge challenge for the next 
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round of gene identification studies will be to pinpoint the genetic factors implicated in 
high-functioning patients with autism. 
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There are many gaps in autism research.  But relatively speaking, I believe the most 
critical gaps are not in any particular type of research, i.e., whether the research is basic 
science or clinical research; postmortem, animal, stem cell, or human research; 
molecular genetic or brain imaging research; infant sibling or affected child, teen, or 
adult research. I believe, like other areas of biomedical and psychological research, the 
most critical gaps are in the quality of the research we do, the depth of the research, 
and its clinical relevance (Chalmers et al., 2014; Ioannidis et al., 2014; 
https://www.sciencemag.org/careers/2014/02/taking-waste-out-biomedical-research). 
 
We still lack an integrative, in-depth understanding of the most basic questions in 
autism research and the most basic problems and challenges faced by affected 
individuals and their families.  Truly high quality and integrative research seems 
necessary to understand the extensive variation in autism, and elucidate the biomedical 
and contextual risk and protective factors, mediating mechanisms and moderators 
across the lifespan. 
 
How to increase value and reduce waste when research priorities are set. 
Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells 
DW, Ioannidis JP, Oliver S. 
Lancet. 2014 Jan 11;383(9912):156-65. doi: 10.1016/S0140-6736(13)62229-1. Epub 
2014 Jan 8. 
PMID: 24411644 
 
Increasing value and reducing waste in research design, conduct, and analysis. 
Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF, 
Tibshirani R. 
Lancet. 2014 Jan 11;383(9912):166-75. doi: 10.1016/S0140-6736(13)62227-8. Epub 




Pat Levitt, PhD, Sara Palencia, CCC-SLP, Allison Knoll, PhD 
Keck School of Medicine 
University of Southern California 
 
The Research Challenge of Biobehavioral Variation and Autism Spectrum Disorder 
 
The pronounced variation of biobehavioral phenotypes in humans reflects an 
evolutionary strategy to optimize survival. This variation is no more apparent than in the 
constellation of symptoms in autism spectrum disorder (ASD). Discerning the biological 
origins of trait variation is complicated. However, a deeper understanding of phenotypic 
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heterogeneity may lead to more successful treatment outcomes. In an attempt to 
mitigate the research challenges inherent in such a varied population, one research 
approach only incorporates individuals with an identical gene mutation, or a diagnosis of 
the same syndrome associated with ASD. Yet even here, there can be substantial 
symptom heterogeneity. Conversely, testing constraints can result in studies that focus 
only on individuals with specific language or cognitive abilities, and yet conclusions are 
applied to the broader population. The issues are magnified because defining and 
capturing variability in complex behaviors such as social communication is challenging 
to measure systematically. Thus, current diagnostic and research tools tend to 
categorize children as demonstrating either “typical” or “atypical” behavioral profiles, 
without addressing variability within those categories. Clinical researchers have some 
appealing new opportunities with the availability of growing clinical and phenomic 
datasets1,2, research capital for advanced information and statistical science. 
Moreover, advanced resolution of behavioral measures is improving the ability to 
discern phenotype patterns. Similar to human studies, research using animal models 
often seeks to minimize genetic and behavioral heterogeneity by focusing on the role of 
a particular causal gene mutation in a single inbred strain of mice. Though important 
discoveries have been made, translation of findings into genetically diverse human 
populations has been difficult. Here, opportunities exist based on strategies used by 
other biomedical fields to systematically interrogate phenotypic variation3,4. Using 
modern tools such as genetic reference panels of vertebrate organisms, paired with 
higher-throughput molecular and behavioral assays, investigators can systematically 
examine the heritable origins of variation5. Tackling heterogeneity experimentally in 
humans or model systems will deepen our understanding of typical and atypical 
development and facilitate innovation of new research-informed ASD interventions. 
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Katherine Loveland, Ph.D. 
University of Texas, Health Science Center at Houston 
 
There is a need for more research on adults with autism, especially those who were not 
diagnosed until adulthood. These are primarily intellectually and verbally able 
individuals, many of whom have achieved major milestones of adulthood such as 
working, living independently, and having a partner. 
 
Life course of individuals with autism. Which factors are related to better adult outcomes 
and which to poorer? Are there cohort-related differences, such that young adults today 
have different risk/protective factors than older adults?  My work suggests that while 
supports and early intervention help youth with autism develop optimally, over-
supporting (continuing supports past the time they are needed, limiting opportunities for 
growth because of fears about failure, etc.) by families delays progress into adulthood 
and reduces independence. 
 
Psychopathology across the life span.  Adults with autism have had many years to 
accrue psychopathology, for which they are at high risk.  However treatments have 
lagged behind.  It is difficult for psychiatrists to treat individuals with autism with 
medication because their response to medication is difficult to predict and often 
unstable.  Research on factors related to atypical response to medication and leading to 
better guidelines for treatment is needed. 
Distinguishing autism in intellectually able adults from conditions such as bipolar 
disorder, personality disorders, and schizophrenia remains a problem. There are many 
psychiatric inpatients with severe mental illness who also have undiagnosed autism, 
and who are at risk for incorrect diagnoses and treatment. Methods to identify and treat 
them more reliably are needed. 
Sexual and identity development in autism. It is known that individuals with ASD are 
over-represented among the LGBTQ+ population. However, almost nothing is known 
about why this should be so. Developmental factors including delayed development of 
identity more generally, difficulty with feeling “different” from others, differing treatment 
of youth with ASD, and other factors should be examined. 
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Overall, I think that adults, severely affected individuals, and non-speaking individuals 
have been neglected in research studies and their needs are great.  I believe that new 
assessments and treatments can be developed that reduce their disability 
significantly.  I also think that there is too little focus on treatment studies and that 
promising new treatments take about 10-15 years to be accepted for reimbursement 
which is the first step toward dissemination.  This time lag reflects the need for two 5-
year trials demonstrating efficacy in order to achieve acceptance. These trials are 
typically sequential thus prolonging the trial process. This needs to be shortened by 
starting new trials of promising treatments before the first trial is completed and starting 
dissemination trials before the second trial is completed.  Many treatments with 
demonstrated effectiveness end up left on the shelf because there is no support for 
dissemination. This also means that successful treatments are present at the few sites 
that participated in the trials but not elsewhere. Meanwhile, many individuals continue to 
get no treatment or older, less effective treatments. This costs money and lives.  A 
related problem is that clinical practice can be 20 years behind the known science and a 
more effective and faster way of disseminating research based advances needs to be 
found. We cannot rely on training programs in medical school and graduate school to 
update knowledge of autism. In our state there are 10-15 television channels reserved 
for public service or government broadcasts, most going unused.  A channel could 
easily be used for disseminating new knowledge as determined by professional groups 
or NIH.  With streaming, a similar service could be provided for updating 
professionals.  I also think there are large holes in assessment instruments. Notable 
examples relate to adaptive function, social cognition, and pragmatic language 
comprehension.  Clinicians and teachers need a relatively quick way to assess real life 
skills in these areas.  Existing tests are insensitive and or long. Teachers have little 
training in recognizing behavior resulting from psychiatric disorders and miss the 
significance of what they see. I would say that research on employment and preparation 
for employment is lacking. Likewise, job programs and vocational programs may have a 
very poor understanding of the limitations of adults with autism resulting in continued 
attempts to match them with jobs that they are unable to do. I do think that the genetic 
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research has made enormous contributions to the understanding of the causes of 
autism with much more to be learned. It also contributes generally to genetics research. 
 
 
Ralph-Axel Mueller, Ph.D. 
Dept. of Psychology 
San Diego State University 
 
After decades of research activity, the neuroimaging community has yet to generate a 
clear picture of critical brain features in ASD. An underlying challenge is that the field 
needs to take heed of its own insights. 
 
A prime example is our awareness of the heterogeneity of the disorder. The vast 
majority of neuroimaging studies in the field have tested for differences between ASD 
and typically developing (TD) groups. This conventional approach may be missing the 
point, if there is no unique pattern of atypical brain features that distinguishes ASD. And 
indeed, with growing awareness of the multitude of genetic risk factors, etiological 
pathways, and outcome phenotypes captured under the clinical umbrella of “ASD”, why 
should we expect the existence of a single atypical pattern? A more promising 
perspective for neuroimaging is to consider comparisons at the group level as a due 
diligence first-pass analysis, to then focus on the truly important question: What is the 
difference, not between ASD and TD groups, but between individuals with ASD? 
Various data-driven clustering techniques are available to pursue the question whether 
such differential patterns indicate subgroups (of individuals with shared brain features) 
within larger ASD cohorts. 
 
Another insight concerns the imaging techniques themselves. For example, we know 
that fMRI does not directly measure neuronal activity or functional connectivity (but 
blood oxygenation related in complex ways to neuronal activity). We know that diffusion 
weighted imaging does not directly measure axonal tract microstructure (but movement 
of water molecules related to tissue organization in rather ambiguous ways). For 
adequate appreciation of findings from these and other techniques, it is crucial to take 
methods for what they are, rather than mistake the neuroscientific interpretation of 
findings for the findings themselves. 
 
Finally, we know (since taking an undergraduate neurophysiology course or the like) 
that brain function and connectivity is exquisitely dynamic. However, the broad 
availability of MRI scanners – and the prodigious versatility of MRI in generating 
biologically relevant contrasts – has led the field to rely predominantly on brain assays 
that neglect dynamics. Of course, there have been decades of EEG research, with a 
more recently added small MEG literature, investigating dynamic brain function in ASD. 
However, MRI and electrophysiology remain largely segregated territories in ASD 
research and much effort in building bridges will be needed for a more comprehensive 
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The Importance of Research on the School-Aged Development of Children with ASD 
 
For many very good reasons early preschool development and adult development are 
often emphasized in research on the natural course, and treatment of Autism Spectrum 
Disorder. However, the development of school-aged children with ASD has received 
relatively little systematic theoretical and empirical consideration in our science. It is not 
clear, though, how a detailed understanding of neurodevelopment and treatment of ASD 
is possible, nor how optimal adult development for all autistic people may be achieved, 
without a comprehensive understanding of the vital and extended period of school-aged 
development.  For example, when considering intervention for ASD after age 5, it is 
important to recognize that instruction in school becomes the most common, longest-
term, and equitable venue for intervention available to all affected children. Indeed, 
children with ASD spend so much time in school it may be difficult to provide 
opportunities for effective intensive intervention anywhere but in school. However, the 
research on learning, social communication and academic development in school-aged 
students has not been a point of emphasis in national funding or research planning. 
Hence, effective interventions are not readily available for schools even though 
numerous studies indicate that the academic achievement and development of school-
aged children with ASD remains poor, for verbally fluent as well as minimally verbal 
children. Not surprisingly, the post-secondary educational, vocational and social 
outcomes for high school students with ASD are well below expectations based on the 
range of IQ observed in these students. In order to improve the outcomes of affected 
youth and adults significantly, and to truly understand the developmental nature of ASD, 
we need to begin to prioritize the study of school-aged children. In particular, we will 
need innovative studies on learning in school-aged children with ASD, and teaching, to 
better leverage time in 1st through 12th grade in order to deliver more effective 
cognitive, social, academic and communication interventions with life-span impact. 
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Relatively few efforts have been to ‘translate’ cellular and rodent models to man (and 
back). For example, it is unknown how well basic models recapitulate the human 
disorder. 
There is a lack of translational research pipelines that take early stage basic science 
findings into man to rapidly test potential new (or repurposed) treatments.  In other 
words basic and clinical sciences largely operate independently of each other. 
Clinical science 
We need to be able to ‘fractionate’ ASD into more biologically homogeneous 
subsamples 
There is a major focus on genes – but these efforts largely use an ‘all comers’ approach 
(i.e. with little or no attempt to address the heterogeneity of ASD).  There needs to be 
more work on gene expression, gene-environmental interaction, and/or how the same 
genetic risk factor can have such divergent outcomes. 
There is a major focus on ‘risk’ – yet relatively little on resilience.  By understanding 
reliance better we are more likely to identify protective factors.  Also our studies of ‘risk’ 
need to better incorporate the role of the environment – and especially during fetal 
development 
As a discipline we often focus mainly on ‘core’ symptoms.  Yet it is the associated 
symptoms (e.g. epilepsy, sleep, anxiety/depression, intellectual disability) that often 
most impact on quality of life.  Hence we could perhaps make more impact in the short 
term by increasing research on those associated symptoms that increase morbidity and 
reduce life expectancy. 
We lack effective treatments.  Also clinical trials - as currently designed - are hugely 
expensive, likely to fail (as they use an ‘all comers’ approach, have high placebo 
response rates, and lack objective outcome measures), and mainly target core 
symptoms. Hence we need to run cheaper, better targeted trials, that use objective 
outcome measures sensitive to change.  In particular we need trials that target 




Jennifer Pinto-Martin, Ph.D., MPH 
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As the human genome becomes ever more accessible, there is a belief by some that 
this will lead to breakthroughs for autism and that genetic testing and genetic 
engineering will reduce the number of new diagnoses. The fact that the genetics of 
autism are so complex and poorly understood, and that many of the genetic alterations 
are the result of de novo mutations and epigenetic processes, makes this highly 
unlikely. The gap in our understanding of the genetics of ASD, and the translation of the 
state of that knowledge into a digestible public message, is one of the major 
deficiencies in the realm of autism research. Families with children with ASD deserve to 
know the genetic contribution for their child and for future children they might have so 
they can make informed family planning choices. But they should also understand that 
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our understanding of the genetics of ASD do not allow us to predict the risk for an 
individual child. To pretend that we can do otherwise is unethical. 
 
Another area in need of sound and replicated research is the area of transition to 
adolescence/ young adulthood. Every family struggles mightily with this transition and 
yet we do not have a solid body of evidence to inform practice in this arena.  High 
functioning individuals with ASD are going to college and yet few colleges or universities 
have support systems in place for these students. Research that addresses the issues 
surrounding transition to independence is critically important to inform policies and 
practices. As the many children with a diagnosis of ASD age into adolescence and 
young adulthood, it is imperative that we understand what predicts the most successful 
transition to independence and to a fulfilling life. To ignore this issue will lock us into a 
responsive as opposed to a proactive approach. 
 
 
Alexia Rattazzi, MD 
Child and Adolescent Psychiatrist 
PANAACEA Argentina 
 
In Latin America, most countries are low and middle-income countries. In these 
countries, autism research infrastructure (number of researchers, full time research 
positions, research oriented organizations, etc.) and funding (both public and private) is 
very limited. ASD research is not only affected by lack of funding, but also by poverty, 
barriers in access to services (both diagnostic and treatment), stigma, limited legislation 
and poor public health infrastructure. To set an example of the lack of data in this 
region: to date, there are very few reliable estimates of ASD prevalence in Spanish-
speaking countries. 
 
In this context, gaps in autism research are very broad. Significant gaps can be seen in 
epidemiology (ASD prevalence and risk factor identification), tool validation 
(developmental surveillance, screening, diagnostic tools), treatment effectiveness (what 
is helpful, when, how much of it, for how long, and for whom) and its measurement, 
effectiveness of community-based and parent mediated interventions, medical 
comorbidities and biomedical interventions, ASD in adulthood, ASD in women, quality of 
life in ASD, inclusive education, amongst others. 
 
Translational and implementation science are significantly relevant in low and middle 
income countries as they focus in connecting autism research and impact on health, 
and promoting the uptake of interventions that have proven effective into routine 
practice with the aim of improving quality of life of individuals with ASD and their 
families. It is very important to prioritize what families and individuals with ASD identify 
as important topics for research. Population oriented research usually gets a significant 
return on investment and this is specially important in funding constrained contexts such 
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Given the emphasis in autism research for interdisciplinary science and for 
biobehavioral approaches to the disorder, there is a surprising gap in neuroscientific 
investigations of treatment effects in ASD. We now have a wealth of neuroscientific 
studies in ASD across the age span, from infancy into adulthood, and that field has 
made major methodological gains in studying brain structure and function in infants and 
young children as well as in persons with more severe disability.  Given our 
understanding of the biology of learning and of action, it seems logical that the positive 
behavior changes and developmental accelerations that occur in the most effective 
early intervention approaches must result from changes in many levels of the brain’s 
learning chemistry and circuitry.  While we have had to rely on animal models for past 
decades to develop hypotheses about neural processes underlying ASD symptoms, 
current brain imaging methods, both structural and functional, appear sophisticated 
enough to examine treatment-related changes in several aspects of central nervous 
system function.  There remains a great deal of dismissal of the effects of early 
treatment among some ASD scientists, perhaps because behavior change data is 
considered to reflect “surface” changes rather than deep systemic changes in core 
neural processes. Demonstration of effects of behavioral treatment on neural 
development or function may elucidate neural mechanisms of change that could lead to 
more effective treatments, both behavioral and pharmacological. Evidence of changes 
at the neural level may also be needed to increase commitment of public health and 
finance systems to the provision of early high quality behavioral treatments.  The bias 
towards funding effective interventions for biological as opposed to developmental 
disorders is easily seen when one compares the amount of money spent to treat a child 
when cancer onsets compared to the amount of money spent to treat a child when 
autism onsets.  And yet ASD is also a biological disorder, and also one that responds to 
specific and focused treatments early in life. The plethora of neuroscientific 
investigations of brain differences of high functioning adults with ASD contrasts sharply 
with the dearth of studies examining how neural systems respond to intensive 
treatments early in life. 
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Increasing early detection and access to specialized intervention in the real world 
 
Within the past 15-20 years, our understanding of the early presentation of autism has 
increased dramatically, as has the number of evidence-based interventions suitable for 
use with very young children. We have learned that early, specialized intervention can 
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have positive effects that we never imagined possible when autism was first introduced 
in the DSM-III. We now have well-validated early screening tools, as well as a variety of 
naturalistic developmental, behavioral, interventions (NDBIs; Schreibman et al., 2015) 
from which to choose. So why haven’t we been able to move the needle in terms of 
early autism detection and engagement in early intervention? 
 
One of the most well-replicated findings in the autism literature is the average age at 
which parents of children with autism first become concerned about their behavior or 
development: 18 months. Yet the average age of an autism diagnosis still hovers 
around 4 years, or later for underserved populations. Granted, there are many obstacles 
to early diagnosis. It’s not easy to diagnose young children whose symptoms overlap 
with those of other disorders. The paucity of providers with specialized training in autism 
contributes to painfully long waiting lists for diagnostic evaluations. And, unfortunately, 
we operate within a medical model in which a formal diagnosis is often required for 
access to specialized interventions. The end result is that many children with autism are 
not identified or served appropriately until they reach school age. 
 
We are unlikely to move the needle unless we are willing to expand our research 
approaches in at least two ways. The first involves extending our research into the 
community, and developing/evaluating feasible ways for front-line providers (i.e., those 
who have early and sustained contact with young children and families) to implement 
evidence-based screening and interventions. The second is moving away from a 
“diagnosis-treatment” healthcare delivery model when early autism symptoms are 
present, and toward a symptom-based preemptive model in which low intensity, yet 
specialized, interventions can be implemented by community providers (e.g., those 
working in Part C Early Intervention programs). While these approaches involve a bit of 
a paradigm shift, the field of implementation science offers some roadmaps for 
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Replication in Autism Research 
 
Many have heard of the “replication problem” in psychological science– the failure of 
subsequent studies to confirm the original results. Further, we often do not know of non-
replications as the publishing field is biased toward novel findings. Identifying the cause 
of non-replication, whether due to a false positive in the first study, a false negative in 
the subsequent study, or other factors, is of serious importance to the integrity of our 
field. Critically, within the field of autism research, non-replication is often attributed to 
sample heterogeneity—which reflects a diverse set of issues itself including the known 
phenotypic diversity of individuals with ASD, historic changes in clinical definitions of 
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ASD, and variability in age and sex within samples. It is practically difficult to match 
groups of individuals across studies, but this limits our ability to seek larger truths about 
the nature of autism without supporting evidence of replication. 
 
How do we move beyond attributing replication issues to differences in group 
characteristics? As sample heterogeneity is not likely to change in the future, 
researchers need to adopt best practices of pre-registration of dependent variable 
specifications and analytic plans, clear quality control metrics, transparency in the 
transformation of raw data to dependent variables, and more investigation of the 
psychometric properties of an experimental measure or dependent variable such as 
validity and reliability. The knowledge of the reliability of the data will be a key 
contribution to eliminating measurement as a contributing factor to non-replication. More 
studies need to include psychometric properties prior to use of a measure in group 
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Despite an improvement over the past five years, there remains a substantial dearth of 
rigorous clinical trials of existing and new interventions. The publication of a 
randomised-controlled trial of a behavioural or pharmacological intervention that 
involves pre-registration, a large sample size, the necessary treatment concealing, and 
high-quality internal validity checks, is still a noticeable and infrequent event in the 
autism research literature. These studies are, of course, highly complex, and require 
considerable resources and planning to execute successfully. However, these 
substantial challenges shrink into the background when juxtaposed with the potential 
benefits. It is now universally acknowledged that ASD is heterogeneous in aetiological 
origin, behavioural presentation, and expression across the life-course. Without a solid 
evidence-base upon which we can provide families with accurate guidance in their 
intervention decisions, we are flying blind amidst these fluctuating variables. The ethical 
implications of this are immense, and this needs to be a key driver in our pursuit to 
make the publication of these studies a more frequent event. There is no doubt that 
cross-site (even, cross-nation) partnerships are critical to this endeavour. It is only 
through targeted funding schemes, the work of professional societies, and critically, the 
will of the scientific research diaspora, that this gap will start to be filled. 
